Molecular Templates Inc
NASDAQ:MTEM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Fairfax Financial Holdings Ltd
OTC:FRFHF
|
CA |
|
ZOA Corp
TSE:3375
|
JP |
Molecular Templates Inc
Goodwill
Molecular Templates Inc
Goodwill Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Goodwill | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Templates Inc
NASDAQ:MTEM
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Goodwill
$35.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Goodwill
$8.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
22%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Goodwill
$18.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Goodwill
$1.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
36%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Molecular Templates Inc
Glance View
Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. The company is headquartered in Austin, Texas and currently employs 261 full-time employees. The company went IPO on 2005-02-04. The firm utilizes its biologic drug platform to design and generate engineered toxin bodies (ETBs). ETBs use a genetically engineered version of the Shiga-like Toxin A subunit (SLTA), a ribosome inactivating bacterial protein. The firm is developing ETBs for various targets, including CD20, CD38, HER2, and PD-L1. CD20 is central to B cell malignancies and is clinically validated as a target for the treatment of lymphomas and autoimmune disease. CD38 has been validated as a clinical target in the treatment of multiple myeloma. HER2 is clinically validated as a target for the treatment of solid tumors including breast and gastric cancer. PD-L1 is central to immune checkpoint pathways and is a target expressed in a variety of solid tumor cancers.
